Overview of Guillain-Barrè Syndrome


Article ID: 4994
Vol 36, Issue 1S1, 2022
DOI: https://doi.org/10.23812/j.biol.regul.homeost.agents.202236.1S1.2
Received: 11 March 2022; Accepted: 11 March 2022; Available online: 11 March 2022; Issue release: 11 March 2022

Abstract

Guillain-Barrè syndrome (GBS) refers to a group of immune-mediated, rapidly progressive polyneuropathies. Before the clinical onset, most patients present with potentially triggering events in their history, including infections and vaccinations. The commonly accepted pathogenic mechanism is an autoimmune response targeting the axons and myelin of peripheral nerves. Diagnosis is based on clinical criteria, though it may be supported by consistent laboratory, neurophysiological and neuroradiological findings, increasing diagnostic reliability. Due to its sudden and invalidating onset, GBS represents a possible cause of access to the emergency room. Therefore, physicians must take into account GBS clinical heterogeneity to promote an early diagnosis and promptly start acute phase treatment and supportive therapies


Keywords

cerebrospinal fluid;flaccid paralysis;Guillain-Barrè Syndrome;immune-mediated;Landry’s paralysis;neuropathy;poliradicoloneuropathy


References

Supporting Agencies



Copyright (c) 2022




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).